Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumorbearing c26 mice

Lucia Gatta, Laura Vitiello, Stefania Gorini, Sergio Chiandotto, Paola Costelli, Anna Maria Giammarioli, Walter Malorni, Giuseppe Rosano, Elisabetta Ferraro

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Trimetazidine (TMZ) is a metabolic reprogramming agent able to partially inhibit mitochondrial free fatty acid β-oxidation while enhancing glucose oxidation. Here we have found that the metabolic shift driven by TMZ enhances the myogenic potential of skeletal muscle progenitor cells leading to MyoD, Myogenin, Desmin and the slow isoforms of troponin C and I over-expression. Moreover, similarly to exercise, TMZ stimulates the phosphorylation of the AMP-activated protein kinase (AMPK) and up-regulates the peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α), both of which are known to enhance the mitochondrial biogenesis necessary for myoblast differentiation. TMZ also induces autophagy which is required during myoblast differentiation and promotes myoblast alignment which allows cell fusion and myofiber formation. Finally, we found that intraperitoneally administered TMZ (5mg/kg) is able to stimulate myogenesis in vivo both in a mice model of cancer cachexia (C26 mice) and upon cardiotoxin damage. Collectively, our work demonstrates that TMZ enhances myoblast differentiation and promotes myogenesis, which might contribute recovering stem cell blunted regenerative capacity and counteracting muscle wasting, thanks to the formation of new myofibers; TMZ is already in use in humans as an anti-anginal drug and its repositioning might impact significantly on aging and regeneration-impaired disorders, including cancer cachexia, as well as have implications in regenerative medicine.

Original languageEnglish
Pages (from-to)113938-113956
Number of pages19
JournalOncotarget
Volume8
Issue number69
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Trimetazidine
Muscle Development
Myoblasts
Cachexia
Stem Cells
Drug Repositioning
Cardiotoxins
Myogenin
Troponin C
AMP-Activated Protein Kinases
Troponin I
Regenerative Medicine
Desmin
Cell Fusion
Autophagy
Organelle Biogenesis
Nonesterified Fatty Acids
Muscle Cells
Regeneration
Neoplasms

Keywords

  • C26 mice
  • Cachexia
  • Metabolism
  • Myogenesis
  • Trimetazidine

ASJC Scopus subject areas

  • Oncology

Cite this

Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumorbearing c26 mice. / Gatta, Lucia; Vitiello, Laura; Gorini, Stefania; Chiandotto, Sergio; Costelli, Paola; Giammarioli, Anna Maria; Malorni, Walter; Rosano, Giuseppe; Ferraro, Elisabetta.

In: Oncotarget, Vol. 8, No. 69, 01.01.2017, p. 113938-113956.

Research output: Contribution to journalArticle

Gatta, Lucia ; Vitiello, Laura ; Gorini, Stefania ; Chiandotto, Sergio ; Costelli, Paola ; Giammarioli, Anna Maria ; Malorni, Walter ; Rosano, Giuseppe ; Ferraro, Elisabetta. / Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumorbearing c26 mice. In: Oncotarget. 2017 ; Vol. 8, No. 69. pp. 113938-113956.
@article{66f7411dcda5461eb03cc5bab32f5c08,
title = "Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumorbearing c26 mice",
abstract = "Trimetazidine (TMZ) is a metabolic reprogramming agent able to partially inhibit mitochondrial free fatty acid β-oxidation while enhancing glucose oxidation. Here we have found that the metabolic shift driven by TMZ enhances the myogenic potential of skeletal muscle progenitor cells leading to MyoD, Myogenin, Desmin and the slow isoforms of troponin C and I over-expression. Moreover, similarly to exercise, TMZ stimulates the phosphorylation of the AMP-activated protein kinase (AMPK) and up-regulates the peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α), both of which are known to enhance the mitochondrial biogenesis necessary for myoblast differentiation. TMZ also induces autophagy which is required during myoblast differentiation and promotes myoblast alignment which allows cell fusion and myofiber formation. Finally, we found that intraperitoneally administered TMZ (5mg/kg) is able to stimulate myogenesis in vivo both in a mice model of cancer cachexia (C26 mice) and upon cardiotoxin damage. Collectively, our work demonstrates that TMZ enhances myoblast differentiation and promotes myogenesis, which might contribute recovering stem cell blunted regenerative capacity and counteracting muscle wasting, thanks to the formation of new myofibers; TMZ is already in use in humans as an anti-anginal drug and its repositioning might impact significantly on aging and regeneration-impaired disorders, including cancer cachexia, as well as have implications in regenerative medicine.",
keywords = "C26 mice, Cachexia, Metabolism, Myogenesis, Trimetazidine",
author = "Lucia Gatta and Laura Vitiello and Stefania Gorini and Sergio Chiandotto and Paola Costelli and Giammarioli, {Anna Maria} and Walter Malorni and Giuseppe Rosano and Elisabetta Ferraro",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23044",
language = "English",
volume = "8",
pages = "113938--113956",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "69",

}

TY - JOUR

T1 - Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumorbearing c26 mice

AU - Gatta, Lucia

AU - Vitiello, Laura

AU - Gorini, Stefania

AU - Chiandotto, Sergio

AU - Costelli, Paola

AU - Giammarioli, Anna Maria

AU - Malorni, Walter

AU - Rosano, Giuseppe

AU - Ferraro, Elisabetta

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Trimetazidine (TMZ) is a metabolic reprogramming agent able to partially inhibit mitochondrial free fatty acid β-oxidation while enhancing glucose oxidation. Here we have found that the metabolic shift driven by TMZ enhances the myogenic potential of skeletal muscle progenitor cells leading to MyoD, Myogenin, Desmin and the slow isoforms of troponin C and I over-expression. Moreover, similarly to exercise, TMZ stimulates the phosphorylation of the AMP-activated protein kinase (AMPK) and up-regulates the peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α), both of which are known to enhance the mitochondrial biogenesis necessary for myoblast differentiation. TMZ also induces autophagy which is required during myoblast differentiation and promotes myoblast alignment which allows cell fusion and myofiber formation. Finally, we found that intraperitoneally administered TMZ (5mg/kg) is able to stimulate myogenesis in vivo both in a mice model of cancer cachexia (C26 mice) and upon cardiotoxin damage. Collectively, our work demonstrates that TMZ enhances myoblast differentiation and promotes myogenesis, which might contribute recovering stem cell blunted regenerative capacity and counteracting muscle wasting, thanks to the formation of new myofibers; TMZ is already in use in humans as an anti-anginal drug and its repositioning might impact significantly on aging and regeneration-impaired disorders, including cancer cachexia, as well as have implications in regenerative medicine.

AB - Trimetazidine (TMZ) is a metabolic reprogramming agent able to partially inhibit mitochondrial free fatty acid β-oxidation while enhancing glucose oxidation. Here we have found that the metabolic shift driven by TMZ enhances the myogenic potential of skeletal muscle progenitor cells leading to MyoD, Myogenin, Desmin and the slow isoforms of troponin C and I over-expression. Moreover, similarly to exercise, TMZ stimulates the phosphorylation of the AMP-activated protein kinase (AMPK) and up-regulates the peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α), both of which are known to enhance the mitochondrial biogenesis necessary for myoblast differentiation. TMZ also induces autophagy which is required during myoblast differentiation and promotes myoblast alignment which allows cell fusion and myofiber formation. Finally, we found that intraperitoneally administered TMZ (5mg/kg) is able to stimulate myogenesis in vivo both in a mice model of cancer cachexia (C26 mice) and upon cardiotoxin damage. Collectively, our work demonstrates that TMZ enhances myoblast differentiation and promotes myogenesis, which might contribute recovering stem cell blunted regenerative capacity and counteracting muscle wasting, thanks to the formation of new myofibers; TMZ is already in use in humans as an anti-anginal drug and its repositioning might impact significantly on aging and regeneration-impaired disorders, including cancer cachexia, as well as have implications in regenerative medicine.

KW - C26 mice

KW - Cachexia

KW - Metabolism

KW - Myogenesis

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=85039071009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039071009&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23044

DO - 10.18632/oncotarget.23044

M3 - Article

AN - SCOPUS:85039071009

VL - 8

SP - 113938

EP - 113956

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 69

ER -